Mutations in fused in sarcoma (FUS) are linked to amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease affecting both upper and lower motor neurons. While it is established that astrocytes contribute to the death of motor neurons in ALS, the specific contribution of mutant FUS (mutFUS) through astrocytes has not yet been studied. Here, we used primary astrocytes expressing a N-terminally GFP tagged R521G mutant or wild-type FUS (WTFUS) and show that mutFUS-expressing astrocytes undergo astrogliosis, damage co-cultured motor neurons via activation of an inflammatory response and produce conditioned medium (ACM) that is toxic to motor neurons in isolation. Time lapse imaging shows that motor neuron cultures exposed to mutFUS ACM, but not WTFUS ACM, undergo significant cell loss, which is preceded by progressive degeneration of neurites. We found that Tumor Necrosis Factor-Alpha (TNFa) is secreted into ACM of mutFUS-expressing astrocytes. Accordingly, mutFUS astrocyte-mediated motor neuron toxicity is blocked by targeting soluble TNFa with neutralizing antibodies. We also found that mutant astrocytes trigger changes to motor neuron AMPA receptors (AMPAR) that render them susceptible to excitotoxicity and AMPAR-mediated cell death. Our data provide the first evidence of astrocytic involvement in FUS-ALS, identify TNFa as a mediator of this toxicity, and provide several potential therapeutic targets to protect motor neurons in FUS-linked ALS.
Mutations in fused in sarcoma (FUS) are linked to amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease affecting both upper and lower motor neurons. While it is established that astrocytes contribute to the death of motor neurons in ALS, the specific contribution of mutant FUS (mutFUS) through astrocytes has not yet been studied. Here, we used primary astrocytes expressing a N-terminally GFP tagged R521G mutant or wild-type FUS (WTFUS) and show that mutFUS-expressing astrocytes undergo astrogliosis, damage co-cultured motor neurons via activation of an inflammatory response and produce conditioned medium (ACM) that is toxic to motor neurons in isolation. Time lapse imaging shows that motor neuron cultures exposed to mutFUS ACM, but not WTFUS ACM, undergo significant cell loss, which is preceded by progressive degeneration of neurites. We found that Tumor Necrosis Factor-Alpha (TNFa) is secreted into ACM of mutFUS-expressing astrocytes. Accordingly, mutFUS astrocyte-mediated motor neuron toxicity is blocked by targeting soluble TNFa with neutralizing antibodies. We also found that mutant astrocytes trigger changes to motor neuron AMPA receptors (AMPAR) that render them susceptible to excitotoxicity and AMPAR-mediated cell death. Our data provide the first evidence of astrocytic involvement in FUS-ALS, identify TNFa as a mediator of this toxicity, and provide several potential therapeutic targets to protect motor neurons in FUS-linked ALS.
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| I N TR ODU C TI ON
Amyotrophic lateral sclerosis (ALS) is an incurable progressive neurodegenerative disease characterized by loss of motor function leading to respiratory failure and death within 3 to 5 years after onset. While the majority of cases occur with no family history and are sporadic (sALS), 10% of patients have an inherited familial form (fALS). fALS cases can be caused by genetic mutations in several genes, including C9orf72, Cu/Zn superoxide dismutase (SOD1), TAR-DNA binding protein 43 (TDP43), fused in sarcoma/translocated in liposarcoma (FUS/TLS) and others. Over 35 mutations have been described in FUS, which has been identified as the primary cause of ALS type 6 (Vance et al., 2009 ).
In healthy controls this multifunctional protein, with roles ranging from DNA repair, transcriptional regulation and mRNA transport (LagierTourenne, Polymenidou, & Cleveland, 2010) , is located primarily in the nucleus (Dormann et al., 2010) ; however, post mortem tissues of FUS-ALS patients reveal cytoplasmic inclusions in affected neurons and glia (Kwiatkowski et al., 2009) . Specifically, carriers of the FUS R521C, R521G, R521H, R524W, or G507N mutations show wide-spread FUS pathology (Blair et al., 2009; Hewitt et al., 2010; Rademakers et al., 2010) , including glial and neuronal cell loss, with increasing distribution of FUS-immunoreactive inclusions in patients with longer disease durations (Suzuki et al., 2012) . Carriers of FUS R521C mutation also show numerous oligodendroglial cytoplasmic inclusions (Mackenzie et al., 2011) . Abundant FUS-immunoreactive pathology is also observed in some sALS cases (Oketa, Higashida, Fukasawa, Tsukie, & Ono, 2013) . This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. V C 2018 The Authors. Glia Published by Wiley Periodicals, Inc.
Several lines of evidence suggest that non-neuronal cells play an active role in driving neuronal dysfunction and neurodegeneration in ALS [reviewed (Lasiene and Yamanaka, 2011) ]. Among these nonneuronal cells, astrocytes are considered key mediators of disease progression in vivo and of motor neuron death in vitro. Chimeric mice in which mutant SOD1 was selectively deleted in astrocytes showed substantially slowed disease progression (Yamanaka et al., 2008) while both rodent and human patient-derived astrocytes have been shown to play a toxic role through the release of, yet identified, soluble factors [reviewed (Haidet-Phillips et al., 2011; Lasiene and Yamanaka, 2011) .
Furthermore, we recently showed that ALS astrocytes, including mut-FUS expressing patient astrocytes, drive up-regulation of the multidrug resistance transporter P-Glycoprotein (P-gp) in endothelial cells of the blood-brain barrier (Qosa et al., 2016) . Astrocytes participate in disease also through a "loss of function" [reviewed (Maragakis and Rothstein, 2006) ] as demonstrated by several human and rodent studies that have observed defects and/or loss of astrocytic glutamate transporter EAAT2/GLT1 for several ALS subtypes including SOD1-ALS (Benkler, Ben-Zur, Barhum, & Offen, 2013; Howland et al., 2002) sALS (Lin et al., 1998) , and C9orf72-ALS (Kwon et al., 2014) . In contrast, studies of astrocytic contributions in TDP-43-mediated ALS have shown conflicting results for both gain and loss-of-function toxicity (Haidet-Phillips et al., 2013; Serio et al., 2013; Tong et al., 2013) . Important questions still remain about astrocytic contributions to disease across different ALS-subtypes, and in this work, we focused on the role played by astrocytes in FUS-linked ALS.
One of the striking hallmarks of ALS is neuroinflammation. This is characterized by the appearance of reactive astrocytes and microglia, as well as macrophage and T-lymphocyte infiltration, further strengthening the evidence that ALS is a noncell autonomous disease where non-neuronal cells actively participate in neurodegeneration (Keller, Gravel, & Kriz, 2009; Levine, Kong, Nadler, & Xu, 1999; Rizzo et al., 2013) . Proinflammatory cytokines such as tumor necrosis factor alpha (TNFa) are upregulated in the spinal cord of ALS patients, and presymptomatically in SOD1 G93A mice (Philips and Robberecht, 2011) .
Inflammation may also have a causal link to ALS as haploinsufficiency of the TBK1 gene, a regulator of inflammatory signaling, has been recently shown to cause ALS and frontotemporal lobe dementia (FTD) (Freischmidt et al., 2015) . Though inflammation and astrocytemediated toxicity have been identified as part of the pathogenic process of ALS [reviewed (Philips and Robberecht, 2011) ], the role of TNFa has been widely debated, at least in the SOD1 mouse model. Approaches to globally eliminate single inflammatory genes in SOD1-ALS mouse models have largely failed to extend survival (Gowing, Dequen, Soucy, & Julien, 2006) and treatment with the TNFa inhibitor, thalidomide, showed some promising results in rodents but did not appear to effectively modulate disease progression in patients and was additionally accompanied by significant side-effects which prevented patients from reaching the target dosage (Stommel et al., 2009 ). However, whether inflammation in general and TNFa in particular play different pathogenic roles in other forms (non-SOD1) of ALS remains to be solved.
Nuclear factor kappa B (NF-jB), an inducible cellular transcription factor found in almost all cell types, plays a key role in regulating the inflammatory response and cellular stress response. Dysregulation of NF-jB has been linked to cancer and neurodegenerative diseases such as Huntington's (Ghose, Sinha, Das, Jana, & Bhattacharyya, 2011) and ALS (Frakes et al., 2014; Prell et al., 2014) . Interestingly, FUS augments NF-OEB-dependent gene expression induced by physiological stimuli such as TNFa (Uranishi, 2001 ). TNFa and NF-OEB have been shown to participate in oscillatory positive feedback loops wherein NF-OEB can regulate TNFa transcription while autocrine and paracrine TNFa signals can in turn trigger patterns of NF-OEB activation (Pe R kalski et al., 2013) . This process plays a key role in regulating inflammatory responses across a variety of cell types.
TNFa is a pleiotropic molecule and well-studied trigger of apoptosis, however, there has recently been an increased interest in its role in CNS physiology and synaptic functions [reviewed (Santello and Volterra, 2012) ]. In addition to classical caspase-8 activation, one mechanism proposed for TNFa-induced neuron death is through the rapid TNFa-induced surface expression changes of AMPA-type glutamate receptors (AMPARs) (Ferguson et al., 2008) . Dysregulation of the precise trafficking can alter neuronal calcium permeability and contribute to excitotoxic vulnerability (Ferguson et al., 2008; Leonoudakis, Zhao, & Beattie, 2008; Olmos and Llad o, 2014) .
Here, using primary astrocytes expressing mutFUS cocultured with primary motor neurons, we studied whether mutFUS-expressing astrocytes mediate motor neuron dysfunction and began identification of the mechanisms by which mutFUS astrocytes damage the motor neurons. We show that mutFUS-expressing astrocytes damage motor neurons through release of toxic factor(s) in the condition medium (ACM).
Using microarray analysis of mutFUS astrocytes and ELISA and Western Blot analysis of mutFUS ACM and cell lysates, we identified secreted TNFa as the predominant factor, whose toxicity is blocked by anti-TNFa neutralizing antibodies. Preventing astrocytic NF-kB activation inhibits TNFa accumulation in the ACM and prevents mutFUS ACM induced motor neuron degeneration. Further, mutFUS ACM alters expression levels of AMPA receptor subunits GluA1 and GluA2 in motor neurons. We show that these changes sensitize motor neurons to AMPA receptor stimulation resulting in increased calcium influx leading to excitotoxic damage and cell death. We also show that these AMPAR changes are a result of TNFa acting on motor neurons. Our data provide the first evidence of astrocytic involvement in FUS-ALS and identify TNFa and components of the AMPA-mediated excitotoxic pathway as potential therapeutic targets for mutFUS-ALS. Strep (Cellgro, 30-002-CI), 1X Fungin (InVivoGen, ant-fn-2), 1X Primocin (InVivoGen, ant-pm-2), 0.25% Gentamicin (Invitrogen, 15710-064).
| Primary rat motor neuron culture
Motor neurons were prepared from e14.5 rat spinal cords. Briefly, 10-20 spinal cords were dissected and mechanically broken into small fragments before being incubated in 0.025% trypsin, followed by DNase.
After a 4% w/v BSA cushion, cells were centrifuged for 55 min without brake through a 10.4% (v/v) Optiprep (Nycomed Pharma) cushion. Collected bands were then spun through a 4% w/v BSA cushion and treated with rat anti-mouse p75NTR antibody for 30 min. Cells were then washed, spun through a 4% w/v BSA cushion and resuspended in goat anti-mouse IgG microbeads for 15 min at 148C. After 4% w/v BSA cushion magnetically labeled cells were loaded into a column attached to a magnetic base and allowed to pass through, collecting the effluent as a negative fraction on a centrifuge tube. After three rinses, the column was removed from the magnet and a flow resister was used to collect the positive fraction. A final 4% w/v BSA cushion was used to collect motor neurons in complete neurobasal medium (Nb-C) (Neurobasal [Gibco, 21103] , B27 supplement (2%), glutamine (0.25%), 2-mercaptoethanol (0.1%), horse serum (2%). Cells were plated on polyornithine-laminin coated coverslips at a density of 5000/18 mm coverslip. Motor neurons were maintained in Nb-C for up to 2.5 weeks.
| Coculture system
A confluent monolayer of astrocytes was plated a minimum of 48 hr before viral treatment in two-chamber slides (Lab Tek, 177380) 
| Quantitative real-time PCR analysis
Measurement of motor neuron GluA1 and GluA2 mRNA levels was made by qPCR. Briefly, DIV 4-5 primary motor neuron cultures were treated with astrocyte conditioned medium and left for 72 hr. Total RNA was isolated by lysing the motor neuron cultures with TRIZOL.
Next, phase separation of the sample was done using chloroform, and the upper aqueous phase was retrieved. RNA was then precipitated by isopropanol and washed with ethanol. The subsequent pellet was
dissolved in DEPC-treated water and those samples were used in a standard reverse transcription protocol using the reverse transcriptase SuperScript IV (Invitrogen). The cDNA was added with TaqMan qPCR primers for rat GAPDH (Rn01775763_g1), and Gria1 (Rn00709588_m1) or Gria2 (Rn00568514_m1). The multi-plex qPCR assay was then performed and analyzed using the QuantStudio 5 RealTime PCR system (ThermoScientific).
| Statistical analysis
Relative fluorescence levels, neurite lengths, % cells remaining, and time to peak data are presented as mean 6 SEM. Statistical significance was evaluated using Student's t test or one-way analysis of variance with post-hoc Tukey's HSD. p < 0.05 or 0.01 was used to determine significance where indicated. A data transformation was used prior to statistical testing in one case for determining differences between neurite lengths as indicated. A logarithmic transformation was required to address a skew in the distribution.
| R E SU LTS

| MutFUS mislocalizes to the cytoplasm and increases GFAP expression in primary astrocytes
Carriers of FUS mutations, including R521G, show widespread FUS pathology, including neuronal and glial cytoplasmic inclusions in the absence of basophilic inclusions (Blair et al., 2009; Hewitt et al., 2010) .
Because the redistribution of nuclear FUS has been observed in a variety of cell culture models (Bosco et al., 2010; Dormann et al., 2010; Farg et al., 2012) , we examined it in our in vitro system of cultured astrocytes transduced with mutFUS. Isolated primary astrocytes were firstly tested for purity using the glutamate transporter GLAST as a marker of mature astrocytes (Supporting Information Figure S1a ,c).
Immunofluorescence analysis showed negligible staining for cellular markers of other forms of glia or neurons (Supporting Information Fig- ure S1B). Viral transduction was used to introduce N-terminally GFPtagged wild-type (WTFUS) and R521G-FUS mutFUS into primary astrocytes with efficiency around 80% (Supporting Information Figure   S1e ). Expression levels of both WT FUS and mutFUS in astrocytes were comparable as shown in western blot analysis (Figure 1c ). Expression of mutFUS led to cytoplasmic mislocalization in 90% of the transduced astrocytes (Figure 1a ,b) thus recapitulating the mislocalization pattern seen in ALS patients. We next asked if mutFUS expression would be sufficient to cause toxicity in astrocytes. Toxicity was measured using CellTiter-Glo Luminescent Cell Viability Assay (CTG), which detects changes in metabolic activity as a measure of overall cell viability (Pedrini et al., 2010) . This assay showed that, while 0.5M thapsigargin used as positive control significantly reduced viability, null virus treatment was not significantly different than either WTFUS or mut-FUS (Supporting Information Figure S1f ). These data suggest that expression of mutFUS alone does not result in astrocytic cell death.
However, immunofluorescence for GFAP, an indicator of astrogliosis was enhanced in mutFUS astrocytes (Figure 1d ). Interestingly the levels of GFAP expression in mutFUS astrocytes were significantly higher compared to WTFUS and null virus (NT) astrocytes (Figure 1e ,f).
WTFUS-expressing astrocytes, on the other hand, only showed a modest increase in GFAP expression compared to NT astrocytes. These results suggest that although mutFUS expression is non-toxic to astrocytes, mutFUS induces enhanced astrogliosis.
3.2 | MutFUS-expressing astrocytes are toxic to cocultured motor neurons
We next tested whether mutFUS-expressing astrocytes are toxic to co-cultured motor neurons. Immunopanned E14.5 primary rat motor neurons were plated on top of a bed of astrocytes previously transduced with FUS (WT or R521G) and allowed to grow in co-culture for 3 days. Cultures were then fixed and stained with antibodies for motor neuron markers choline acetyltransferase (ChAT), and the 75-kDa low-affinity neurotrophin receptor (p75-NTR). We then assessed neurite lengths in both groups to gauge toxic phenotype as previously done by others (Han et al., 2013; Lasiene and Yamanaka, 2011) .
Motor neurons were selected based on ChAT-positive immunostaining (Supporting Information Figure S1d ), and neurite length measured using p75-NTR (Anderson et al., 2004) . Contrary to motor neurons co-cultured with WTFUS-astrocytes, motor neurons plated on mut-FUS containing astrocytes had less extensive branching and shorter neurites ( Figure 2a ). To quantify reductions in neurite length, tracings of individual neurons were used (Figure 2b ) to create cumulative frequency plots (Figure 2c ). Motor neurons cocultured with mutFUS astrocytes, exhibited a 34% 6 6% reduction in neurite length ( Figure   2d ), compared to those cocultured with WTFUS-expressing astrocytes. As additional controls, we demonstrated that damage to neurite morphology is also evident in motor neurons co-cultured with mutant, but not WT, SOD1 astrocytes (Figure 2c ). These data suggest that mutFUS expression in astrocytes can damage neurite morphology of wild-type neurons.
| MutFUS astrocytic conditioned medium is toxic to motor neurons
We next asked if the mutFUS-mediated defect in neurite morphology was due to a contact-dependent mechanism or the release of soluble factor(s). Motor neurons were cultured alone and treated with ACM from transduced astrocytes (Figure 3a) . Motor neurons were then analyzed for cumulative neurite lengths as they were in Figure 2 . We observed reduced neurite length in motor neurons treated with mut-FUS but not WTFUS ACM (Figure 3b ). While neurite length has been previously used reliably as a measure of neuronal viability, nevertheless, it is not a measure of neuronal degeneration. Thus, to measure motor neuron degeneration over time after exposure of ACM, we tracked individual neurons in 24-hr intervals by time lapse-imaging ( Figure 3c ).
Neurons were marked as dead by their disappearance from the field of imaging or obvious morphological indicators such as fragmentation as shown in Figure 3c . At a time point of 96 hr after ACM treatment, we measured a significant motor neuron loss (43% 6 3.7%) in cultures treated with mutFUS ACM compared to WT FUS ACM (11% 6 1.9%) ( Figure 3d ). As a comparison, neuronal death caused by mutant SOD1
ACM is shown (Figure 3d ). These results indicate that motor neuron death triggered by mutFUS astrocytic expression involves a soluble factor(s).
| MutFUS astrocytes secrete TNFa
Because mutFUS ACM is sufficient to damage the motor neurons, we used a combination of gene expression profiling and protein analysis to begin to identify astrocytic changes that might contribute to toxic . Densitometry data are presented as mean 6 SEM. GFAP levels were normalized to the GAPDH loading control and presented relative to nontransduced control. Statistical significance was evaluated using one-way ANOVA, n 5 3, *p < 0.01 as we have seen ACM toxicity. The top pathway hit that we predicted would influence broad secretomic changes was the TNF-alpha and NF-KB signaling pathway (Table 1) , which has been studied extensively for its role in mediating pro-inflammatory cell-to-cell signaling. On the basis of these results, we then measured common pro-inflammatory cytokine levels in the WTFUS and mutFUS ACM by ELISA (Figure 4b ).
Among those, we identified TNFa as the most highly altered secreted factor in mutFUS ACM (3.8-fold increase over WTFUS ACM). Further, we validated this result using a second ELISA containing a new set of sandwich antibodies, and found mutFUS ACM contains significantly more TNFa compared to WTFUS or Non-transduced (NT) ACM ( Figure   4c ). Additionally, we probed astrocyte cell-lysates for total TNFa via western blot, and found that astrocytes expressing mutFUS have increased expression levels compared to WTFUS and NT astrocytes (Figure 4d ). Together, these data clearly show that TNFa is aberrantly upregulated and secreted by mutFUS astrocytes.
| TNFa neutralization in mutFUS ACM rescues motor neuron degeneration and death
To test the role of TNFa in mutFUS-mediated toxicity, we plated motor neurons in isolation and imaged individual cells before and after SEM. Data were assessed after a logarithmic transformation to normalize the distribution and statistical significance was evaluated using Student's t test, >100 neurons traced per condition, n 5 4, *p < 0.05. The data shown are the raw untransformed data in the original units | 1023 lead to pharmacoresistance (Qosa et al., 2016) . Thus, reducing astrocytic TNFa production in patients may have therapeutic potential for multiple features of disease.
| Pharmacological inhibition of NF-OEB in astrocytes rescues motor neuron neurite loss and cell death
Astrocytes can respond to inflammatory cytokines such as TNFa by inducing classical NF-kappaB (NF-OEB) signaling to regulate inflammation and drive the expression of many chemokines and molecules upregulated in ALS. NF-OEB is activated in glia in fALS and sALS patients, and astrocytes derived from human postmortem ALS patients showed NF-OEB as the highest-ranked regulator of inflammation in gene array data (Lasiene and Yamanaka, 2011; Swarup et al., 2011) . 
| MutFUS ACM triggers AMPA receptor changes and AMPA receptor-mediated cell death in motor neurons
Because TNFa has been shown to induce surface expression changes of AMPA-type glutamate receptors (AMPARs), leading to excitotoxicity (Ferguson et al., 2008; Leonoudakis et al., 2008; Santello and Volterra, 2012) , we hypothesized that the aberrant release of TNFa by mutFUS astrocytes may also lead to AMPA receptor dysregulation in motor neurons. To test this, we treated motor neurons with ACM GluA2 expression compared to motor neurons treated with WTFUS ACM (Figure 7a-c) . We then determined whether AMPAR changes occur also at the mRNA level. We therefore probed GluA1 and GluA2 mRNA in ACM-treated motor neurons and found GluA1 mRNA to be significantly increased at a time point of 72 hr in the mutFUS ACM condition (Figure 7d ). Although GluA2 mRNA remain unchanged at this time point, with the significant increase in GluA1 mRNA levels, the GluA1/GluA2 ratio significantly shifts, similar to the immunofluorescence data shown in Figure 7a -c. GluA2 subunits confer calcium impermeability on AMPARs and their decrease relative to GluA1 is associated with the addition of more calcium-permeable AMPARs (Mansour, Nagarajan, Nehring, Clements, & Rosenmund, 2001) . Given that AMPA receptor subunit composition was altered in motor neurons exposed to mutFUS ACM, we hypothesized that AMPA receptor stimulation in these neurons may result in a higher calcium entry. To test this idea, we measured intracellular calcium levels following AMPA stimulation in motor neurons treated with ACM, using the genetically encoded calcium sensor GCaMP6m (Figure 7e ). Motor neurons treated with mutFUS ACM for 48 hr showed significantly larger intracellular calcium increases following stimulation with 10 lm AMPA 1 10 lm cyclothiazide compared to WT ACM. When comparing peak GCaMP6m DF/F 0 we found that mutFUS ACM treated motor neurons displayed a 1.8-fold increase over WTFUS ACM-treated neurons on average (Figure 7f ). To test the idea that excitotoxic damage might be contributing to neuronal death in our conditioned medium experiments we sought determine whether pharmacological inhibition of AMPA receptors could offer neuroprotection from mutFUS ACM. We treated motor neurons with the AMPA/Kainate receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) alongside treatments of mutFUS astrocytic media. Addition of CNQX significantly increased survival (79% 6 1.3% compared to 59% 6 2.5%) in neurons treated with mutFUS ACM (Figure 7g ). Taken together, these results suggest that mutFUS astrocytes sensitize motor neurons to excitotoxic damage. Shown are the top 20 most altered pathways as determined by the combined number of significantly altered genes within each pathway along with the number of changes and the significance score ranking. In bold is the TNF-alpha and NF-KB signaling pathway which was chosen as a candidate pathway for further analysis based on previous evidence of role of the TNF-alpha and NF-KB pathways in regulating cytokines and inflammatory cellto-cell signals. . Peak values are presented as mean 6 SEM and statistical significance was evaluated using Student's t test. n 50, *p < 0.01. (g) Quantification of motor neurons remaining after 96 hr treatment with ACM 6 10 lM CNQX (6-cyano-7-nitroquinoxaline-2,3-dione). Survival data are presented as mean 6 SEM and statistical significance was evaluated using Student's t test, > 60 neurons counted per condition, n 3, *p < 0.01
| D I SCUSSION
Here, we show for the first time that ALS-causative mutations in FUS can cause noncell autonomous motor neuron degeneration. While expression of mutFUS-R521G is not toxic to astrocytes, these cells adopt a reactive phenotype as evidenced by an increase in GFAP expression and a selective increase in some pro-inflammatory cytokines. Importantly, these astrocytes become toxic to motor neurons via the release of harmful factor(s). Interestingly, mutFUS astrocyte toxicity is driven by a cascade of events that include astrocytic NF-kB activation, release of TNFa and AMPA receptor alterations in motor neurons that allow for dysregulated calcium influx and cell death.
Perhaps with the exclusion of TDP-43 astrocytes, it is widely recognized that ALS astrocytes actively kill motor neurons through the release of toxic factor(s) (Haidet-Phillips et al., 2013) . While the identification of factors responsible for transmitting toxicity of mutant SOD1
and sporadic ALS astrocytes is still under intense investigation, our work identifies a key toxic factor in mutFUS astrocytes. We show that mutFUS expressing astrocytes have increased expression of TNFa and increased production of soluble TNFa. This is unique to mutFUS astrocytes as mutant SOD1 astrocytes do not release TNFa, as we have shown using patients-derived iPSc-astrocytes cocultured with iPSc-endothelial cells (Qosa et al., 2016) . Elevated TNFa production has been observed in a number of neurodegenerative diseases including ALS [reviewed (Philips and Robberecht, 2011)] . TNFa is a pleiotropic molecule that can be produced by a number of different celltypes, including astrocytes (Chung and Benveniste, 1990; Santello and Volterra, 2012) . In the CNS in particular, TNFa signaling is complex, and its role in regulating synaptic transmission both physiologically and pathologically is increasingly being appreciated (Ferguson et al., 2008; Leonoudakis et al., 2008; Olmos and Llad o, 2014; Santello and Volterra, 2012) . Importantly, soluble recombinant TNFa has been shown to be directly toxic to human fetal tissue derived neurons and motor neuronlike NSC-34 in vitro and knockout of TNFa receptors prevents motor neuron cell death in an axonal injury mouse model, indicating that TNFa can damage motor neurons (D'Souza, Alinauskas, McCrea, Goodyer, & Antel, 1995; He, Wen, & Strong, 2002; Raivich et al., 2002) .
Accordingly, in our model, the TNFa produced by mutFUS astrocytes is toxic to motor neurons and motor neuron death can be rescued by neutralizing anti-TNFa antibodies. In contrast to TNFa, we did not see
TNFa neutralization in mutFUS-ACM prevents AMPA receptor alterations: (a) 9 DIV motor neurons were treated with ACM for 72 hr following which they were probed for GluA1 and MAP-2 by immunocytochemistry. A representative image is shown along with cropped images of the highlighted region of a single neuron for MAP-2 (green) and GluA1 (red). For TNFa neutralization, ACM was incubated with a TNFa neutralizing antibody (nAb) prior to treatment of motor neurons. (b) Quantification of dendritic GluA1 signal. ROIs along the dendrites of motor neurons were selected on the basis of MAP-2 labeling and fluorescence intensity was measured. A total of >50 dendrites from >15 cells were analyzed per condition. Fluorescence levels are presented as mean 6 SEM. Statistical significance was evaluated using one-way ANOVA, n 5 5, *p < 0.05 In addition to TNFa, our study also points to astrocytic NF-kB as a driver of neurodegeneration. It is well-known that NF-kB plays a role in both driving the expression of TNFa and mediating TNFa signaling pathways (Pe R kalski et al., 2013). In our mutFUS astrocytes, inhibiting the activation of NF-kB reduces the production of TNFa and protects motor neurons, strongly suggesting that NF-kB and TNFa pathways are inter-related. In ALS, NF-kB has been shown to be activated in glial cells in vitro and in postmortem tissues of fALS and sALS and its dysregulation has been shown to have a significant impact on neuroinflammation (Frakes et al., 2014; Haidet-Phillips et al., 2011; Prell et al., 2014; Swarup et al., 2011) . Interestingly, studies by Frakes et al. (2014) have found that microglia containing mutant SOD1 also increase their production of TNFa and acquire a neurotoxic phenotype that can be (Swarup et al., 2011; Uranishi, 2001 ) and augment its function.
The study of FUS and NF-kB interactions however is limited to just a single study that was carried out prior to discovery of FUS as an ALS gene. Future studies will be required to uncover more about interactions between NF-kB and mutFUS variants and the role of these interactions in ALS.
In line with a number of other studies we also found AMPARs as an important component of neuronal toxicity in our model. AMPAR changes have been demonstrated as a contributor in both in vitro and in vivo models of SOD1-ALS (Van Damme et al., 2007) , in vitro studies of C9orf72-ALS (Donnelly et al., 2013) , postmortem studies of sporadic ALS (Kwak, Hideyama, Yamashita, & Aizawa, 2010) , and cellautonomous studies of FUS-ALS (Udagawa et al., 2015) . Motor neurons are known to be especially vulnerable to AMPA-mediated excitotoxicity due to an unusually high density of Ca
21
-permeable AMPA receptors and low calcium buffering ability (Palecek, Lips, & Keller, 1999; Vandenberghe et al. 2000) . Furthermore, neighboring astrocytes are known to be key regulators of these AMPA receptors (Beattie, 2002; Van Damme et al., 2007) . Here, we show that the AMPAR GluA2 subunits are decreased, while GluA1 subunits are increased in the dendrites of motor neurons exposed to mutFUS ACM but not WTFUS ACM. Edited GluA2 subunits are known to confer calcium impermeability to AMPARs and, therefore, we hypothesized that motor neuron cell death following mutFUS ACM treatment might be attributable to an excitotoxic mechanism involving this AMPAR change. Corroborating with this hypothesis, we found intracellular calcium levels following AMPA stimulation are elevated in motor neurons exposed to mutFUS ACM. Using an AMPA receptor antagonist we then rescued the motor neuron death resulting from mutFUS ACM, indicating the involvement of excitoxicity in our model. Our results extend current evidence for AMPAR involvement in ALS and could prompt further studies of noncell autonomous AMPA regulation in ALS and FUS-ALS.
Interestingly, several groups have reported a role for TNFa as a regulator of surface AMPAR expression in spinal cord motor neurons. These studies have shown that TNFa triggers a change in AMPARs which can promote a shift towards surface expression of GluA2-lacking receptors (Ferguson et al., 2008; Ogoshi et al., 2005; Stellwagen, 2005) . Although these studies focused on the rapid effects of short-term TNFa exposure, we have demonstrated here that longer incubations with TNFacontaining mutFUS-ACM, not only alter GluA1 & GluA2 protein levels but also trigger an increase mRNA levels for GluA1. Furthermore, our results indicate that AMPAR changes driven by mutFUS-ACM can be attributed to TNFa signaling, as ablation of soluble TNFa in the ACM prevents an increase in dendritic GluA1 protein levels.
In addition to paracrine effects on motor neurons, astrocytes also express both TNFa receptors (TNFR1 and TNFR2) and TNFa can act on astrocytes to cause a diverse set of changes (Fischer, Wajant, Kontermann, Pfizenmaier, & Maier, 2014; Tezel, Li, Patil, & Wax, 2001) Thus, TNFa released from mutFUS astrocytes may contribute to astro- Despite numerous studies showing both fALS and sALS astrocytes being toxic to motor neurons, the identification of a toxic factor remained elusive. Here we demonstrate that mutant FUS astrocytes contribute to motor neuron death and the principal factor of this toxicity is TNFa secreted from these astrocytes. Although our studies clearly show mutFUS astrocytes are primed to secrete toxic levels of TNFa, the underlying mechanism for such an aberrant secretion remains to be studied. In future studies, it will also be interesting to understand whether changes to the RNA/DNA binding properties of mutant FUS or other cellular stress induced by the mislocalization of mutant FUS mediates the aberrant NF-kB activation and production of TNFa.
In summary, we have extended a significant body of work pointing to a key role for astrocytes in ALS by demonstrating for the first time 
